{
    "clinical_study": {
        "@rank": "100726", 
        "acronym": "TEBCABG", 
        "arm_group": [
            {
                "arm_group_label": "TENS CABG", 
                "arm_group_type": "Experimental", 
                "description": "Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention."
            }, 
            {
                "arm_group_label": "P-TENS CABG", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33)."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will test the hypothesis that transcutaneous electrical nerve stimulation\n      (TENS) may attenuate peripheral vasoconstriction and to improve blood flow redistribution\n      during handgrip exercise in acute myocardial infarction (AMI) patients after Coronary\n      Arterial Bypass Graft Surgery (CABG)."
        }, 
        "brief_title": "Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Thirty-eight patients will be randomized to a (4 times/day; 30 min/session) for 5-day\n      program of TENS (n = 20) or to placebo-TENS (P-TENS, n = 18) applied on cervical region\n      (C7-T4). Acute sympathetic stimulation by cold pressor test (CPT), Maximal voluntary\n      contraction (MVC), Femoral blood flow (FBF) and femoral vascular conductance (FVC) will be\n      measured as primary outcome pre and post-CABG, even as the 6-minute walk test (6-MWT),\n      Inspiratory and expiratory muscle strength (PImax and PEmax) and \u03b2-endorphin as a secondary\n      clinical parameters. In addition, amount of opioid analgesic and pain intensity also will be\n      measured throughout at first 24 hours after CABG (immediately, 6, 12 and 24 hours)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  a previous history of more than 1 vessel coronary artery disease,\n\n          -  lifelong abstinence from tobacco, and\n\n          -  formal indication for CABG, according to established guideline.\n\n        Exclusion Criteria:\n\n          -  Patients older than 70 years of age, with chronic renal failure, or with unstable\n             angina in the 48 h prior to CABG, moderate or severe valve disease, complex cardiac\n             arrhythmias, stroke, and/or inability to exercise the lower limbs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "48 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777659", 
            "org_study_id": "12-0317"
        }, 
        "intervention": {
            "arm_group_label": [
                "TENS CABG", 
                "P-TENS CABG"
            ], 
            "description": "Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.", 
            "intervention_name": "Transcutaneous electrical nerve stimulation", 
            "intervention_type": "Device", 
            "other_name": [
                "TENS", 
                "electrical stimulation"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "exercise", 
            "neuromodulation", 
            "blood flow", 
            "exercise capacity"
        ], 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Porto Alegre", 
                    "country": "Brazil", 
                    "state": "Rio Grande do Sul", 
                    "zip": "90035-007"
                }, 
                "name": "Hospital de Clinicas de Porto Alegre"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery", 
        "other_outcome": [
            {
                "description": "A visual analog scale (VAS) for assessing current pain intensity will be  used to evaluate pain from 0 to 10, where 0 means no pain and 10 indicates severe pain, being applied on the first and on the 5th day after CABG .", 
                "measure": "Pain Intensity", 
                "safety_issue": "Yes", 
                "time_frame": "5 day"
            }, 
            {
                "description": "During the first 24 h (immediately, 6, 12 and 24 h) after CABG, the amount of additional analgesic dose (pethidine hydrochloride (HCl) 20 mg, maximum 1 mg/kg/day) was measured for patients in both groups.", 
                "measure": "Opioid Analgesic Amount", 
                "safety_issue": "Yes", 
                "time_frame": "5 day"
            }, 
            {
                "description": "Ten milliliters of venous blood will be taken by the phlebotomist. 3 ml of which will be stored in ethylenediaminetetraacetic acid (EDTA) for analysis of a differential white cell count. Seven ml of blood will be divided between an EDTA tube and a lithium heparin (LH) gel tube. These blood samples will be centrifuged and frozen until assayed. \u03b2-endorphin was measured by sandwich enzyme immunoassay (ELISA) kit (Phoenix Pharmaceuticals, Inc., USA).", 
                "measure": "\u03b2-Endorphin Analysis", 
                "safety_issue": "Yes", 
                "time_frame": "5 day"
            }
        ], 
        "overall_official": {
            "affiliation": "Federal University of Rio Grande do Sul", 
            "last_name": "Gaspar R Chiappa, Dr, ScD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The ultrasound Doppler system will be equipped with two linear array transducers operating at an imaging frequency of 7- 8 megahertz (MHz). The common femoral artery of the left leg will be insonated distal to the inguinal ligament, 2-3 cm proximal to the bifurcation. Using femoral artery diameter and mean blood velocity (MBF), femoral blood flow (FBF) was calculated as MBF \u03c0 x (vessel diameter/2)2 x 60. Femoral vascular resistance (FVR) and femoral vascular conductance (FVC) were calculated as (MBP/FBF) and (FBF/MBP * 100 mm Hg), the conductance multiplied by 100 mmHg so that the conductance units will be similar to the units of femoral blood flow (10, 45). The magnitude of reduction FVC (expressed in %) was calculated as vascular conductance during exercise (% change) - conductance at rest (% change) expressed by % of baseline.", 
            "measure": "Blood flow redistribution - baseline and 5 days later", 
            "safety_issue": "Yes", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777659"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital de Clinicas de Porto Alegre", 
            "investigator_full_name": "GASPAR ROGERIO DA SILVA CHIAPPA, Principal Investigator", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Inspiratory and expiratory muscle strength testing were performed using a pressure transducer (MVD-500 V.1.1 Micro Hard System, Global Med, Porto Alegre, Brazil). Maximal inspiratory (PImax), and maximal static expiratory pressure (PEmax) were measured as previously described.", 
            "measure": "Inspiratory and Expiratory Muscle Function", 
            "safety_issue": "Yes", 
            "time_frame": "5 day"
        }, 
        "source": "Hospital de Clinicas de Porto Alegre", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Brasilia", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital Sao Joao", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hospital de Clinicas de Porto Alegre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}